• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Amgen to Acquire Five Prime Therapeutics for $1.9B

    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions

    CureVac, Novartis Ink COVID Vax Mfg. Pact

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Reed-Lane Facility Virtual Tour

    CureVac, Novartis Ink COVID Vax Mfg. Pact

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    WuXi AppTec Completes OXGENE Acquisition

    Trends in Solid Oral Dosage Delivery
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reed-Lane Facility Virtual Tour

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    Four Female Leaders Appointed to Cell & Gene CDMO

    Strata Oncology Unveils Strata PATH Trial
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Reed-Lane

    PCI Pharma Services

    Adare Pharma Solutions

    Cytovance Biologics
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    PCI Pharma Services

    Syngene

    Cytovance Biologics

    Adare Pharma Solutions

    Aphena Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    CDMO Market Trends

    Vivek Sharma, CEO, Piramal Pharma Solutions, discusses outsourcing trends, opportunities, and the capabilities needed for today’s (bio)pharma pipelines.

    CDMO Market Trends
    Related CONTENT
    • Asymchem
    • Legacy Pharma Solutions
    • PCI Pharma Services
    • Piramal Pharma Solutions
    • Catalent Pharma Solutions
    Kristin Brooks, Managing Editor, Contract Pharma03.06.19
    Soaring drug development costs and increasingly complex therapies have pharma and biopharma companies outsourcing to contract development and manufacturing organizations (CDMOs) to help keep costs down and to gain access to comprehensive solutions.

    With the growth in the sterile injectable market, high potency compounds, and antibody drug conjugates, sponsors are seeking out advanced technologies and expertise, driving demand for integrated services from proof-of-concept to commercialization.

    Vivek Sharma, chief executive officer of Piramal Pharma Solutions (PPS) discusses outsourcing trends, opportunities for CDMOs, and the capabilities needed for today’s pharma/biopharma pipelines.

    Contract Pharma (CP): How has the CDMO market evolved over the last few years?

    Vivek Sharma (VS):
    The pharmaceutical industry is evolving towards targeted drug delivery platforms, complex molecules such as biologics and niche indications, all of which require a wider range of development capabilities and manufacturing capacity to ensure accelerated speed to market. As a result pharmaceutical companies, both large and small, look for strategic, integrated partners, who can seamlessly deliver on multiple verticals, thereby reducing complexity of their supplier network.

    The CDMO industry is consolidating on a large scale to become integrated in capabilities, capacities and geographies. The top five CDMOs account for 15% of the total CDMO market size, growing between 5-7% over the next five years, faster than their big pharma counterparts.1 CDMOs in niche areas might forward and/or back integrate, to offer more integrated value chains to customers.

    Integrated CDMOs are also developing new service models focused on resource flexibility and shared risk. Innovative business models may include pharma site divestiture to a CMO with committed volumes for a set number of years, risk-share models lowering upfront costs with success tied to milestone events, and fixed price early development projects. Customers are also now more willing to co-invest with the CDMO, when capital requirements are high; moving from vendor transactions to strategic partnerships. Private equity is also playing a significant role in the CDMO industry, providing the capital for capability and capacity expansion and management expertise.

    CP: What is the biggest opportunity you see for the company in the CDMO space?

    VS:
    Piramal constantly tracks market dynamics and engages with customers to collaboratively identify future needs. The high growth sterile injectable space is expected to reach $657 billion by 2024 at a growth rate of 8%. Additionally, oncology continues to grow, with 60% of all high potency drugs being developed for cancer. We see these as prime opportunities and hence in response to this, we have expanded our North American network, acquiring Coldstream Laboratories for injectable capabilities and Ash Stevens for high potency API capabilities.

    With respect to parenterals, the bigger opportunities lie in complex formulations like liposomes and lyophilization. Apart from this, biologics are also making a mark in industry. Antibody drug conjugates (ADCs) are now proven targeted therapies in oncology and we see a healthy pipeline in this area for our Grangemouth, UK facility serving customers from proof-of-concept to commercialization of ADC.

    CP: What are some of the latest motivators for sponsors with respect to outsourcing?

    VS:
    As pharmaceutical companies face increasing cost pressures and as the complexity of drug candidates rises, they turn to CDMOs with a motivation of reducing capital investment and at the same time gaining access to specialized expertise. The major motivation for sponsors apart from cost reduction is the impeccable track record the CDMOs carry in terms of product quality, on-time delivery, regulatory compliance, safety, and value.

    Also, CDMOs offer long-term supply security and share the risks due to their robust financial structures. Sponsors also get access to advanced technologies and expertise like high potent manufacturing and isolator technology for injectables, which otherwise requires investment for separate containment area. This helps the sponsor to focus on their core competencies.

    In addition, CDMOs take care of end-to-end supply chain needs that reduces a sponsor’s effort associated with management of inventory and logistics. This in turn helps to eliminate penalties associated with rescheduling due to delays. CDMOs offering integrated services help reduce time to market by performing all steps under one roof.

    CP: What new capabilities are required for today’s drug products? What specific services are increasingly being outsourced?

    VS:
    The pharmaceutical contract manufacturing market is projected to grow at an annualized rate of 4.8% between 2018 and 2028.4 At the same time, pharmaceutical and biotech companies are increasingly selective while choosing a CDMO partner due to risks associated with development of new chemical entities (NCEs). Hence, CDMOs with diverse and advanced capabilities are a top priority.

    The new capabilities required for today’s drug products are laid on the principles of patient compliance, reduced costs and of course better efficacy of the drug. The shift from ampoules to vials and now pre-filled syringes (PFS) is a classic example in sterile injectables. Also, few technologies categorized as complex injectables have been proven to be better drug delivery systems like liposomes, nanoparticles, microemulsion, microparticles, micelles, PEGylation, etc. These are termed as New Drug Delivery Systems (NDDS). There are also capability advancements in oral solids (OSDs), like controlled/modified release dosages. The examples of NDDS for OSDs are Osmotic Drug Delivery Systems (OROS) with laser drill technology, encapsulation, layered tablets, etc.

    Out of the total outsourced API market, generic APIs hold the major share of the market (84%) while the remaining (16%) are branded APIs. Within the contract formulations market, solid dose compounds lead with ~50% followed by injectables (33%) and semi-solid/liquid compounds (17%). The growth is likely to be driven by injectables due to increased focus on targeted therapies in disease areas like oncology.

    CP: What is your perspective on where R&D is going and where do you think some of the biggest opportunities lie?

    VS:
    The pharmaceutical industry has seen a surge in NME approvals, from 46 in 2017 to 59 in 2018, with biologics, particularly antibodies forming a large portion. Research and development is now moving beyond traditional small molecules and conventional biologics to newer modalities such as ADCs, nucleic acid therapeutics and peptides.

    Additionally, owing to the necessity and higher likelihood of regulatory approval of niche drugs for orphan indications, we see a focused research effort towards rare diseases. Orphan drugs are forecasted to grow at a rate of ~11% by 20242; at double the rate of the non-orphan drug market. Both Big Pharma and biotech companies recognize the value of making these drugs accessible to patients at shortened timelines, thereby gaining a higher return on investment.

    Oncology is another area of focus, forming ~11% of the global therapeutics market as per research by IQVIA.3  Drugs for oncology are composed of high-potency active pharmaceutical ingredients (HPAPIs) which require containment and specialized infrastructure. We will continue to see significant investment of both CDMOs and pharmaceutical companies to manufacture high potency drugs.

    While biologics and orphan drugs are on the rise, we also expect R&D efforts on oral solid drugs to remain consistent owing to their ease of patient compliance and reduced manufacturing complexity. Innovation in oral solid drugs is likely to be in the areas of improved drug delivery and bioavailability, while enhancing efficacy. 


    Vivek Sharma currently serves as the chief executive officer of Piramal Pharma Solutions (PPS), a global provider of contract research, development and manufacturing services for the life sciences industry. PPS offers integrated solutions from discovery through development and commercialization, with research and manufacturing facilities in North America, Europe, and Asia. Mr. Sharma has led Piramal Pharma Solutions through rapid growth with a strategy that augments organic growth with synergistic, well timed, acquisitions. He joined the Piramal group in 2011 to lead the Piramal critical care business. By focusing on strategies that emphasized operational efficiencies and geographical expansion, he led the business towards improved profitability and rapid growth. The critical care business is now the third largest in the world, and the fastest growing inhalation anesthetics company globally. Mr. Sharma is based in Boston, MA and has over 25 years of global management experience.




    References
    1. Kurmann Partners. Pharma M&A Report 2018  http://www.kurmannpartners.com/fileadmin/user_upload/_temp_/KP_Pharma_M_A_Report_2018_-_medium.pdf
    2. Evaluate Pharma, 2018. Orphan Drug Report 2018  http://info.evaluategroup.com/rs/607-YGS-364/images/OD18.pdf
    3. IQVIA. Global Oncology Trends 2018:Innovation, Expansion and Disruption  https://www.iqvia.com/institute/reports/global-oncology-trends-2018
    4. Pharmaceutical Contract Manufacturing Market (2nd Edition), 2018-2028  https://www.researchandmarkets.com/reports/4542472/pharmaceutical-contract-manufacturing-market-2nd
    Related Searches
    • biologics
    • outsourced
    • capacity
    • contract pharma
    Suggested For You
    Asymchem Asymchem
    Legacy Pharma Solutions Legacy Pharma Solutions
    PCI Pharma Services PCI Pharma Services
    Piramal Pharma Solutions Piramal Pharma Solutions
    Catalent Pharma Solutions Catalent Pharma Solutions
    Regis Custom Pharma Regis Custom Pharma
    Softweb Solutions Softweb Solutions
    Vetio Animal Health Vetio Animal Health
    Adare Pharma Solutions Adare Pharma Solutions
    Contracting And Outsourcing Exhibitor List Contracting And Outsourcing Exhibitor List
    Preparing For Your CDMO Selection Process Preparing For Your CDMO Selection Process
    CDMO Outsourcing Trends CDMO Outsourcing Trends
    Piramal Unveils New cGMP Kilo Lab Suite for APIs Piramal Unveils New cGMP Kilo Lab Suite for APIs
    Outsourcing Strategies: Skills and Heritage Outsourcing Strategies: Skills and Heritage
    Integrating Antibody Purification and Conjugation Integrating Antibody Purification and Conjugation

    Related Features

    • Solid Dosage/Semi-solids
      Hygienic Packaging Technology

      Hygienic Packaging Technology

      Growing consumer demand for health products highlights hygienic packaging.
      John Brown, Vice President of Global Marketing, Selig 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Trends in Solid Oral Dosage Delivery

      Trends in Solid Oral Dosage Delivery

      Capsule demand continues to rise due to this delivery system’s versatility.
      Anita Solanki, Milind Biyani and Jnanadeva Bhat, PhD , ACG Capsules 03.01.21

    • Information Technology
      5 Reasons Paper Has No Place in Contract Manufacturing

      5 Reasons Paper Has No Place in Contract Manufacturing

      Digital solutions create more efficient manufacturing processes and eliminate delays.
      Dave Edwards, Chief Revenue Officer, MasterControl 03.01.21


    • Drug Delivery | Parenterals
      Injectable Drug Delivery Trends

      Injectable Drug Delivery Trends

      How medication trends are driving the shift to patient-friendly drug delivery systems.
      Peter Soelkner, Managing Director, Vetter 03.01.21

    • Pharmaceutical Manufacturing  Equipment Trends

      Pharmaceutical Manufacturing Equipment Trends

      Demand for flexibility remains the driving force behind equipment systems.
      Kristin Brooks, Managing Editor, Contract Pharma 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Oral Solids:   Market & Technology Trends

      Oral Solids: Market & Technology Trends

      Oral solids remain the preferred route of drug delivery due to their cost-effectiveness, ease of manufacturing, and patient-friendly dose form options.
      Tim Wright, Editor, Contract Pharma 03.01.21


    • Nutraceutical Manufacturing:  Meeting the Challenges of Today, Planning for  Tomorrow

      Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow

      Companies continue balancing high demand, supply disruption, and worker safety during the pandemic.
      Sean Moloughney, Editor, Nutraceuticals World 03.01.21

    • 2021 Contract  Manufacturing Survey

      2021 Contract Manufacturing Survey

      Our fourth annual audience poll indicates continued reliance on manufacturing partners, particularly for small businesses.
      Sean Moloughney, Editor, Nutraceuticals World 03.01.21

    • APIs
      Small Molecule Development Trends

      Small Molecule Development Trends

      A Q&A with Cambrex Edinburgh’s site director, Mark Benger.
      Tim Wright, Editor, Contract Pharma 03.01.21


    • APIs | Cytotoxics and High Potency Manufacturing
      Challenges & Opportunities Facing Small & Emerging Biopharma Companies

      Challenges & Opportunities Facing Small & Emerging Biopharma Companies

      A Q&A with Christian Dowdeswell, vice president and head of commercial development for small molecules at Lonza.
      Tim Wright, Editor, Contract Pharma 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Medicated Chewing Gum: A Modern Oral Drug Delivery System

      Medicated Chewing Gum: A Modern Oral Drug Delivery System

      Development and manufacture of medicated chewing gum continues to gain momentum.
      Rukayat Adedeji, Contributing Writer 03.01.21

    • APIs
      Small Molecule API CDMO: A Capital Intensive Business?

      Small Molecule API CDMO: A Capital Intensive Business?

      Exploring small molecule API market trends.
      Dr. Michele Jermini and Dr. Enrico Polastro, Contributing Writers 03.01.21


    • Serialization
      Serialization: Level 5 Solution

      Serialization: Level 5 Solution

      Why a Level 5 solution is required for small pharma companies to fully harness serialization investment.
      Steve Wood, President & CEO, Covectra 03.01.21

    • Solid Dosage/Creams/Ointments
      High Drug Loading Amorphous Solid Dispersions

      High Drug Loading Amorphous Solid Dispersions

      A Novel Tablet Architecture for Amorphous Solid Dispersions to Achieve High Drug Loadings
      Deanna Mudie and Aaron Stewart, Lonza 01.27.21

    • Parenterals
      Parenteral Drug Delivery Trends

      Parenteral Drug Delivery Trends

      A Q&A with Lubrizol Life Science Health’s CDMO Division President, Rob Lee.
      Kristin Brooks, Managing Editor, Contract Pharma 01.27.21

    Trending
    • Catalent Acquires Delphi Genetics
    • Four Female Leaders Appointed To Cell & Gene CDMO
    • Matica Biotechnology Breaks Ground On Cell And Gene Therapy Site
    • Celonic Group Announces Plans For New Facility In Switzerland
    • BMS Expands Cell Therapy Manufacturing Capabilities
    Breaking News
    • Amgen to Acquire Five Prime Therapeutics for $1.9B
    • Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    • CureVac, Novartis Ink COVID Vax Mfg. Pact
    • Innoforce and dMed Enter Development Collaboration
    • Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    IFT Transitions 2021 Annual Event to Digital Experience
    NY Federal Judge Enters Permanent Injunction Against Dietary Supplement Manufacturer
    Statins May Contribute to Vascular Calcification by Inhibiting Vitamin K-Dependent Proteins
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies Adds Benjamin Woeste as Territory Sales Manager
    Maroon Group Acquires Cary Company's Raw Materials, Specialty Chemicals Distribution Business
    Matt Fogel Named Mule-Hide's Territory Manager – Southern Virginia
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    EchoNous Expands Its Kosmos Hardware Platform
    Medtronic Begins Trial to Assess Novel Ablation Tech to Treat AFib
    Europe's Cross-Border Medtech Deal Activity Rises in Q4 2020
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Amgen to Acquire Five Prime Therapeutics for $1.9B
    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    CureVac, Novartis Ink COVID Vax Mfg. Pact
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Estée Lauder Establishes Equity and Engagement Center of Excellence
    L'Oreal On How It Will Shape Beauty's Future at Today's Transparency Summit
    C.O. Bigelow Earns Praise as NYC's Oldest Family-Run Apothecary
    Happi

    Latest Breaking News From Happi

    Avon Launches Vegan Skin Care Line
    Inolex Appoints VP Marketing
    Decorté Launches AI Diagnostics in US
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Henkel publishes 30th Sustainability Report
    Avery Dennison Smartrac launches new Circus Pro inlays
    Springfield Solutions highlights digital label embellishments
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    FPInnovations Develops Biodegradable Mask
    Sani Professional Sanitizing and Disinfecting Products Approved by EPA
    Autefa Solutions Offers Fully Automated Line for Protective Mask Production
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Bioventus Appoints Managing Director, China and Asia Pacific
    Full-Year Sales Down 12 Percent at Zimmer Biomet
    Lincotek Medical Expands Coatings and Additive Capacity
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login